dihexa clinical trials status 2026 A Look at Pennsylvania in April Diabetes Clinical Trials: Emerging Trends

Close one nostril with your finger

When youre deficient in a certain vitamin, you can experience side effects

FDA added dysesthesia to injectable semaglutide labeling, January 2025

The goal is to better understand whether someone is in an optimal state to perform safety-sensitive tasks, not to replace compliance procedures but to enhance them

Overcoming the Shortcomings of Peptide-Based Therapeutics

Compared to healthy controls with no renal impairment, the Cmax and AUC of nirmatrelvir in subjects with mild renal impairment was 30% and 24% higher, in subjects with moderate renal impairment was 38% and 87% higher, and in subjects with severe renal impairment was 48% and 204% higher, respectively